Skip to main content

$1.14 -0.01 (-0.44%)

High

$1.17

Low

$1.13

Trades

1,304

Turnover

$2,983,889

Volume

2,606,681
30 June 2023 at 4:10pm
Register to track MSB and receive email alerts.

Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients

StockBot

416,823 posts

MSB released this announcement to the ASX on 31 May 2022, 10:03. The announcement is not marked as price sensitive, and is 2 page(s) in length and 179.19kb in size.

You can view all announcements from MSB and see how they appear on a price chart on the announcements page.

At the date of this announcement, MSB was 8.053% short sold according to ASIC data. It was ranked the 13th most shorted stock on the ASX. It remains ranked 40th as of the latest reported data (05 May 2025).

Other Recent Announcements from MSB
Change of Director's Interest Notice 13 June 2023, 8:56
Mesoblast Director Appointed to Strategic Advisory Role 5 June 2023, 9:41
MSB Reports Q3 Financial Results and Operational Highlights 26 May 2023, 8:32
Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients 31 May 2022, 10:03
Ceasing to be a substantial holder 30 May 2022, 8:19
Becoming a substantial holder 20 May 2022, 8:21
Litigation Update 19 May 2022, 10:07
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track MSB and receive email alerts.